RecruitingEarly Phase 1NCT06137040

Timely Administration of IV Magnesium Sulfate in Patients With a Moderate Asthma Exacerbation


Sponsor

University of Oklahoma

Enrollment

100 participants

Start Date

Nov 30, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This study aims to identify whether early administration of magnesium sulfate in moderate asthma exacerbations can potentially avoid admission, decrease length of stay in the emergency department (ED), decrease length of stay (LOS) in the general hospital floor vs pediatric intensive care unit (PICU), and decrease the need for respiratory support.


Eligibility

Min Age: 5 YearsMax Age: 17 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether giving magnesium sulfate through an IV earlier during a moderate asthma attack improves outcomes in children treated in the emergency department. Magnesium sulfate is a medication that helps relax the muscles around the airways. **You may be eligible if...** - Your child is between 5 and 17 years old - Your child is being treated in the emergency department for a moderate asthma flare-up - You (the parent or caregiver) speak English **You may NOT be eligible if...** - Your child has other serious lung conditions besides asthma (such as chronic lung disease), cerebral palsy, congenital heart disease, depends on a tracheostomy, or has myasthenia gravis - Your child is pregnant - Parents or caregivers do not speak English Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMagnesium Sulfate within the first hour

The experimental group will receive 40-50 mg/kg of IV magnesium sulfate will be given to the experimental group alongside the first line asthma therapies (ie inhaled beta agonists, IV steroids). This will be given with a 20 mL/kg normal saline bolus (max 1000 mL) to avoid possible hypotension. 15-19 kg: 750 mg 20-29 kg: 1000 mg 30-39 kg: 1500 mg \>40 kg: 2000 mg

OTHERNo Magnesium sulfate within the first hour

The control group will not receive IV magnesium sulfate within the first hour of treatment.


Locations(1)

Oklahoma Children's Hospital

Oklahoma City, Oklahoma, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06137040


Related Trials